drugset
drugset / Trial / NCT04180982

A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia

NCT04180982 ↗

Phase 2 Unknown 84 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of the study is to assess the Safety and Efficacy of SHR4640 and Febuxostat in patients with Hyperuricemia.

Timeline

Start
2019-12-03
Primary completion
2020-07-30
Completion
2020-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Febuxostat Small molecule — Oral
Subject SHR4640 Small molecule — Oral

Indications

No indication recorded.